抄録
The purposes of this in vitro study were twofold: 1) to estimate the activities of peripheral blood lymphocytes (PBLs) obtained from patients with recurrent or residual malignant gliomas and treated with recombinant interleukin 2 (HL-2), and 2) to investigate a simpler method by which rIL-2 can be used to activate enough killer cells having sufficient cytotoxicity for adoptive immunotherapy (AIT).
PBLs were obtained from eight patients with recurrent or residual intracranial malignant gliomas (5 glioblastomas and 3 anaplastic astrocytomas). The cells were suspended in complete medium (CM) consisting of RPMI 1640 containing 10% heat-inactivated human serum, 100 IU/ml penicillin G, and 50μg/ml streptomycin. The cell suspensions were divided into the following seven groups and cultured for 10 days. Group I: Culture in CM only; Group II: Culture in CM which, for the first 48 hours, contained 0.2% phytohemagglutinin (PHA) ; Group III: Culture in CM containing 0.2% PHA; Group IV: Culture in CM containing 0.4 U/ml rIL-2; Group V: Culture in CM containing 0.8 U/ml rIL-2; Group VI: Culture in CM containing 2.0 U/ml rIL-2; Group VII: Culture in CM containing 0.4 U/ml rIL-2 which, for the first 48 hours, contained 0.2% PHA. Cell numbers, morphological changes, various lymphocyte subsets, and natural killer (NK) activity were analyzed.
The cells cultured with rIL-2 (Groups IV, V, and VI) exhibited prominent NK activity, but after 10 days the cell numbers were inadequate for AIT. Treatment with rIL-2 containing 0.2% PHA for the first 48 hours (Group VII) resulted in slightly weaker NK activity than occurred in Groups IV, V, and VI, but cell proliferation was extensive. The cells in Group VII were estimated to be suitable for anti-tumor AIT.
